Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial

27 August 2021 (00:00 - 00:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Matthew Segar

Texas Heart Institute, Houston (United States of America)

4 More presentations in this session

Presentation thumbnail

Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.

Professor M. Banach (Lodz, PL)

Abstract Slides Video

Presentation thumbnail

Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis

Doctor W. Sun (Shatin, HK)

Abstract Slides Video

Presentation thumbnail

Changes in EPA and DHA during supplementation with Omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial

Doctor P. Myhre (Oslo, NO)

Abstract Slides Video

Presentation thumbnail

Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial

Doctor F. Cosentino (Stockholm, SE)

Abstract Slides Video

Access the full session

Session thumbnail

Can we improve outcomes by targeting metabolic risk?

The Event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

You may be interested in

Congress Presentation

Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting

Congress Presentation

Cardiovascular risk reduction: should we target pre-diabetes?

Webinar

Prevention of heart failure in diabetic patients at population level

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources